Nycomed Amersham results climb in first half of 2000

Growth in medical imaging procedure volume worldwide helped contribute to strong financial results from Nycomed Amersham Imaging in the first half of the year. The Nycomed unit contributed $560.5 million (U.S.), a gain of 8% over the prior year, with operating profit of $138.8 million, up 19%. In April, Nycomed Amersham reorganized its imaging operations into two businesses, medical diagnostics and therapy products.

In its x-ray business, Nycomed reported particularly strong growth in the U.S., with sales of $116.3 million, up 9% over the previous period. Worldwide, Nycomed generated x-ray contrast sales of $188.1 million, a gain of 5% over the previous year. Sales of the firm’s Visipaque agent grew 14% to $41.3 million. While price pressure in the x-ray contrast sector is evident in some European markets, this has been offset by volume growth and some increases in other sectors, according to the London-based firm.

In MRI, revenues grew 8% to $44.5 million, with sales of Nycomed Amersham's Omniscan agent up 12% to $43.8 million. The vendor’s radiopharmaceutical business grew 10% to $213.2 million. This growth was driven largely by the firm’s Myoview cardiac agent, which gained 31% to $55 million.

By AuntMinnie.com staff writers
August 8, 2000

Related Reading

Nycomed inks deal with Premier for prostate brachytherapy, August 3, 2000

Nycomed Amersham joins Global Healthcare Exchange, July 26, 2000

Contrast study favors Nycomed agent in coronary procedures, May 10, 2000

Nycomed and Mallinckrodt settle patent suits, May 8, 2000

Nycomed spotlights OncoSeed study, May 4, 2000

Nycomed reports healthy imaging growth, March 1, 2000

Copyright © 2000 AuntMinnie.com

Page 1 of 3625
Next Page